TRB and LUR have been shown to activate CD4+ and CD8+ T-cells as well, promoting the adaptive anti-tumour immune response, inducing their infiltration in vivo and the proliferation of activated effector T-cells in vitro [43,100,102,103]. The gene discussed is CD4; the disease is neoplasm.